The Drug-Specific Propensity Regarding the Acquisition of Fluoroquinolone Resistance in Escherichia coli: An in vitro Challenge and DNA Mutation Analysis

References

• Aliabadi S, Anyanwu P, Beech E, et al. Effect of antibiotic stewardship interventions in primary care on antimicrobial resistance of Escherichia coli bacteraemia in England (2013–18): a quasi-experimental, ecological, data linkage study. Lancet Infect Dis. 2021;21(12):1689–1700. doi:10.1016/S1473-3099(21)00069-4
   PubMed Web of Science ®Google Scholar
• Critchley IA, Cotroneo N, Pucci MJ, Jain A, Mendes RE. Resistance among urinary tract pathogens collected in Europe during 2018. J Glob Antimicrob Resist. 2020;23:439–444. doi:10.1016/j.jgar.2020.10.020
   PubMed Web of Science ®Google Scholar
• Thompson DK, Muradyan AG, Miller ASF, Ahiawodzi PD. Antibiotic resistance of Escherichia coli urinary tract infections at a North Carolina community hospital: comparison of rural and urban community type. Am J Infect Control. 2022;50(1):86–91. doi:10.1016/j.ajic.2021.08.032
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Yamamoto S, Takahashi S, et al. The third national Japanese antimicrobial susceptibility pattern surveillance program: bacterial isolates from complicated urinary tract infection patients. J Infect Chemother. 2020;26(5):418–428. doi:10.1016/j.jiac.2020.01.004
   PubMed Web of Science ®Google Scholar
• Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the infectious diseases society of America and the European society for microbiology and infectious diseases. Clin Infect Dis. 2011;52(5):e103–e120. doi:10.1093/cid/ciq257
   PubMed Web of Science ®Google Scholar
• Pédeboscq S, Issa N, Lahouati M, Labadie A, Pereyre S, Camou F. Impact of a 5-year antimicrobial stewardship program focusing on fluoroquinolone prescriptions. Int J Pharm Pract. 2021;29(6):616–621. doi:10.1093/ijpp/riab047
   PubMed Web of Science ®Google Scholar
• Ott SR, Allewelt M, Lorenz J, Reimnitz P, Lode H. German Lung Abscess Study Group. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection. 2008;36(1):23–30. doi:10.1007/s15010-007-7043-6
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria. CLSI Guideline M45. 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. CLSI Supplement M100. 30th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.
   Google Scholar
• Li X, Mariano N, Rahal JJ, Urban CM, Drlica K. Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin. Antimicrob Agents Chemother. 2004;48(11):4460–4462. doi:10.1128/AAC.48.11.4460-4462.2004
   PubMed Web of Science ®Google Scholar
• Pitondo-Silva A, Martins VV, Silva CFD, Stehling,EG. Conjugation between quinolone-susceptible bacteria can generate mutations in the quinolone resistance-determining region, inducing quinolone resistance. Int J Antimicrob Agents. 2015;45(2):119–123. doi:10.1016/j.ijantimicag.2014.07.018
   PubMed Web of Science ®Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):e169–e183. doi:10.1093/cid/ciaa1478
   PubMed Web of Science ®Google Scholar
• Jwair NA, Al-Ouqaili MTS, Al-Marzooq F. Inverse Association between the Existence of CRISPR/Cas Systems with antibiotic resistance, extended spectrum β-lactamase and carbapenemase production in multidrug, extensive drug and pandrug-resistant Klebsiella pneumoniae. Antibiotics (Basel). 2023;12(6):980. doi:10.3390/antibiotics12060980
   PubMed Web of Science ®Google Scholar
• Doi Y, Park YS, Rivera JI, et al. Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis. 2013;56(5):641–648. doi:10.1093/cid/cis942
   PubMed Web of Science ®Google Scholar
• Kohanski MA, DePristo MA, Collins JJ. Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Mol Cell. 2010;37(3):311–320. doi:10.1016/j.molcel.2010.01.003
   PubMed Web of Science ®Google Scholar
• Bergallo C, Jasovich A, Teglia O, et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized Phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis. 2009;63(1):52–61. doi:10.1016/j.diagmicrobio.2008.09.001
   PubMed Web of Science ®Google Scholar
• Li Y, Zhu D, Peng Y, et al. A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia. Curr Med Res Opin. 2021;37(4):693–701. doi:10.1080/03007995.2021.1885362
   PubMed Web of Science ®Google Scholar
• Thurber KM, Arnold JR, Narayanan PP, Dierkhising RA, Sampathkumar P. Comparison of intravenous and oral definitive antibiotic regimens in hospitalised patients with Gram-negative bacteraemia from a urinary tract infection. J Glob Antimicrob Resist. 2019;18:243–248. doi:10.1016/j.jgar.2019.03.013
   PubMed Web of Science ®Google Scholar
• Takayanagi N, Kagiyama N, Ishiguro T, Tokunaga D, Sugita Y. Etiology and outcome of community-acquired lung abscess. Respiration. 2010;80(2):98–105. doi:10.1159/000312404
   PubMed Web of Science ®Google Scholar
• Yagci D, Yoruk F, Azap A, Memikoglu O. Prevalence and risk factors for selection of quinolone-resistant Escherichia coli strains in fecal flora of patients receiving quinolone therapy. Antimicrob Agents Chemother. 2009;53(3):1287–1289. doi:10.1128/AAC.01228-08
   PubMed Web of Science ®Google Scholar
• Richard P, Delangle MH, Raffi F, Espaze E, Richet H. Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora. Clin Infect Dis. 2001;32(1):162–166. doi:10.1086/317551
   PubMed Web of Science ®Google Scholar
• de Lastours V, Chau F, Roy C, Larroque B, Fantin B. Emergence of quinolone resistance in the microbiota of hospitalized patients treated or not with a fluoroquinolone. J Antimicrob Chemother. 2014;69(12):3393–3400. doi:10.1093/jac/dku283
   PubMed Web of Science ®Google Scholar
• Fantin B, Duval X, Massias L, et al. Ciprofloxacin dosage and emergence of resistance in human commensal bacteria. J Infect Dis. 2009;200(3):390–398. doi:10.1086/600122
   PubMed Web of Science ®Google Scholar
• Wise R, Lockley RM, Webberly M, Dent J. Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrob Agents Chemother. 1984;26(2):208–210. doi:10.1128/AAC.26.2.208
   PubMed Web of Science ®Google Scholar
• Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997;32(2):101–119. doi:10.2165/00003088-199732020-00002
   PubMed Web of Science ®Google Scholar
• Nakashima M, Uematsu T, Kosuge K, Umemura K, Hakusui H, Tanaka M. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother. 1995;39(1):170–174. doi:10.1128/AAC.39.1.170
   PubMed Web of Science ®Google Scholar
• Wise R, Gee T, Marshall G, Andrews JM. Single-dose pharmacokinetics and penetration of BMS 284756 into an inflammatory exudate. Antimicrob Agents Chemother. 2002;46(1):242–244. doi:10.1128/AAC.46.1.242-244.2002
   PubMed Web of Science ®Google Scholar
• Lawrence LE, Wu P, Fan L, et al. The inhibition and selectivity of bacterial topoisomerases by BMS-284756 and its analogues. J Antimicrob Chemother. 2001;48(2):195–201. doi:10.1093/jac/48.2.195
   PubMed Web of Science ®Google Scholar
• Atac N, Kurt-Azap O, Dolapci I, et al. The Role of AcrAB–TolC efflux pumps on quinolone resistance of E. coli ST131. Curr Microbiol. 2018;75(12):1661–1666. doi:10.1007/s00284-018-1577-y
   PubMed Web of Science ®Google Scholar
• Thanassi DG, Cheng LW, Nikaido H. Active efflux of bile salts by Escherichia coli. J Bacteriol. 1997;179(8):2512–2518. doi:10.1128/jb.179.8.2512-2518.1997
   PubMed Web of Science ®Google Scholar
• Totsuka K, Sesoko S, Fukase H, Ikushima I, Odajima M, Niwayama Y. Pharmacokinetic study of lascufloxacin in non-elderly healthy men and elderly men. J Infect Chemother. 2020;26(3):231–239. doi:10.1016/j.jiac.2019.09.010
   PubMed Web of Science ®Google Scholar
• John TM, Deshpande A, Brizendine K, Yu PC, Rothberg MB. Epidemiology and outcomes of community-acquired Escherichia coli pneumonia. Open Forum Infect Dis. 2021;9(1):ofab597. doi:10.1093/ofid/ofab597
   PubMed Web of Science ®Google Scholar
• Neuman M. Comparative pharmacokinetic parameters of new systemic fluoroquinolones: a review. Chemioterapia. 1987;6(2):105–112.
   PubMedGoogle Scholar
• Wiessler M, Pool BL. Mutagenic properties of N-cyclopropyl and N-allyl-N-nitroso compounds. Studies on the nature of alkylating species. Carcinogenesis. 1984;5(5):635–639. doi:10.1093/carcin/5.5.635
   PubMed Web of Science ®Google Scholar
• Al-Ouqaili MTS. Molecular detection and sequencing of SHV gene encoding for extended-spectrum β-lactamases produced by multidrug resistance some of the Gram-negative bacteria. Int J Green Pharm. 2018;12(4):S910–S918. doi:10.22377/ijgp.v12i04.2274
   Google Scholar